All news

Teva R&D chief Eric Hughes to leave; company keeps $6-7 billion innovative medicines target

StockTitan (GlobeNewswire) · · AI-summarised by FinFlash

Teva Pharmaceutical said Eric Hughes, executive vice president of global R&D and chief medical officer, will leave the company after accepting an outside offer, staying on through the coming months. David Gardiner, head of innovative medicines and clinical development, becomes R&D transition lead effective immediately, reporting to CEO Richard Francis, while a successor search begins. Teva said its priorities are unchanged, including its ambition for $6 billion to $7 billion of innovative medicines revenue by 2030.

So What?

A senior R&D departure adds execution risk to Teva's pivot toward branded drugs; watch pipeline milestones and how the stock reacts given the reaffirmed 2030 goal.

Read original source

TEVA company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.